Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs

Rheumatology (Oxford). 2025 Jun 1;64(6):3234-3241. doi: 10.1093/rheumatology/keaf090.
No abstract available

Keywords: axSpA, ankylosing spondylitis; biologics; extra-musculoskeletal manifestations; guideline; inflammatory bowel disease; management; psoriasis; recommendations; targeted synthetic DMARDs; treatment; uveitis.